2025 Annual Report on Investor Protection Work
The company upholds the mission of "caring for life with high-quality products and serving the public with high-quality services," with pharmaceutical manufacturing as its core business. It adheres to a development path driven by innovation in research and development and marketing, aiming to become a leading pharmaceutical and healthcare group in China. In 2025, against the backdrop of continuous transformation in the pharmaceutical industry, the company, guided by its strategic positioning as a "pharmaceutical and healthcare enterprise with traditional Chinese medicine as its foundation, innovation as its leader, and quality and efficiency as its priorities," has stabilized its production and operations while continuously promoting innovation in new drug R&D, enhancing operational quality, and efficiency.
The company attaches great importance to the protection of investor rights and interests, adheres to the concept of sustainable development, and is committed to creating long-term value for shareholders, diligently fulfilling its responsibilities as a listed company. In 2025, the company further improved the quality of information disclosure and investor relations management, continuously refined its investor protection mechanisms, and promoted positive interaction with investors through sustained cash dividends, truthful, transparent, and compliant information disclosure, and close communication with investors. These measures aim to safeguard the legitimate rights and interests of all investors, especially small and medium investors, and create tangible value returns for them.